Biologic Considerations in Targeting Brain tumors for Boron Neutron Capture Therapy

  • Rolf F. Barth


Malignant gliomas and metastatic brain tumors constitute a major group of neoplasms for which there is virtually no effective treatment at the present time. In the United States ~12,000 deaths are attributable to the former and ~ 80,000 – 100,000 to the latter, annually.1 The survival of a group of 1578 patients with primary brain tumors who had been entered into three Radiation Therapy Oncology Group Protocols between 1974 and 1989 has been carefully studied by Curran et al. by means of recursive partitioning analysis.’ Survival was related to the following parameters: 1. age at presentation (<50 versus >50 years) 2. pathologic diagnosis of either astrocytoma with anaplastic foci (AAF) or glioblastoma multiforme (GBM) 3. mental and physical performance status. Using recursive partitioning analysis with amalgamation for the different variables, a series of survival curves were generated that showed very clear differences between those patients who had favorable prognostic indicators i.e. <50 yrs, diagnosis of AAF, high performance status versus those who had unfavorable indicators i.e. >50 yrs, diagnosis of GBM, low performance status. The latter group had median survival times (MeSTs) ranging from 4.6 to 11.1 months and a 2 year survival rate of 9% for those patients with the worst prognostic indicators (classes IV-VI combined) compared to MeSTs of 17.9–58.6 mos and 2 yr survival rate of 55% for those patients who had favorable indicators (class I-III combined). If future clinical trials of BNCT focus on those patients who have the worst prognostic indicators (classes IV-VI), it should be possible to determine in a relatively short time (i.e. 2 years) and with a small group of patients (15–24) if there is therapeutic efficacy, as evidenced by prolongation of survival time (using a test for 2 independent proportions, power 95%, α = 0.05, M.L. Moeschberger, personal communication). The present review will focus on biologic considerations that may be important for targeting both primary and metastatic brain tumors for Boron Neutron Capture Therapy (BNCT).


Brain Tumor Malignant Glioma Linear Energy Transfer Boron Neutron Capture Therapy Recursive Partitioning Analysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E.R. Laws, Jr. and K. Thapar, Brain tumors. CA Cancer J. Clin. 43: 263–271, 1993.Google Scholar
  2. 2.
    W.J. Curran, Jr., C.B. Scott, J. Horton, et al., Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials..1. Natl. Cancer Inst. 85: 704–710, 1993.CrossRefGoogle Scholar
  3. 3.
    E.C. Halperin, P.C. Burger, D.E. Bullard, The fallacy of the localized supratentorial malignant glioma. Int. J. Radiat Oncol. Biol. Phys. 15: 505–509, 1988.PubMedCrossRefGoogle Scholar
  4. 4.
    B.L. Maria, T.A. Eskin, R.G. Quisling, Brainstem and other malignant gliomas: 11. Possible mechanisms of brain infiltration by tumor cells. J. Child Neurol. 8: 292–305, 1993.PubMedCrossRefGoogle Scholar
  5. 5.
    S. Yamada, Y. Takai, K. Nemoto, et al., Radioresponse and prognosis of malignant glioma. Tohoku J. Exp. Med. 167: 79–87, 1992.Google Scholar
  6. 6.
    J.S. Loeffler, E. Alexander, Ill, F.H. Hochberg, et al., Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int. J. Radial. Oncol. Biol. Phys. 19: 1455–1462, 1990.CrossRefGoogle Scholar
  7. 7.
    P.A. Stewart, C.L. Farrell, C.L., R.F. Del Maestro, The effect of cellular microenvironment on vessels in the brain. Part 1: Vessel structure in tumour, peritumour and brain from humans with malignant glioma. Int. J. Radiat. Biol. 60: 125–130, 1991.PubMedCrossRefGoogle Scholar
  8. 8.
    E.A. Neuwelt, J. Howieson, E.P. Frenkel et al., Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood brain barrier modification in glioblastoma. Neurosurgery 19: 573–582, 1986.Google Scholar
  9. 9.
    W. Yang, R.F. Barth, J.H. Rotaru, M.L. Moeschbcrger, D.E. Carpenter, D.D. Joel, M.M. Nawrock, and J.H. Goodman. Enhanced survival of Glioma bearins rats folllowing boron neutron capture therapy with blood brain barrier disruption and intracarotid injection of boronophcnylalanine. J. Neuro-oncol. 1997 (In press).Google Scholar
  10. 10.
    E.A. Neuwelt, P.A. Barnett, K.E. Hellström et al., Effect of blood-brain barrier disruption on intact and fragmented monoclonal antibody localization in intracerebral lung carcinoma xenografts. J. Nucl. Med. 35: 1831–1841, 1994.PubMedGoogle Scholar
  11. 11.
    L.W. Davis, Presidential address: Malignant glioma-a nemesis which requires clinical and basic investigation in radiation oncology. Int. J. Radiat. Oncol. Biol. Phys. 16: 1355–1365, 1989.PubMedCrossRefGoogle Scholar
  12. 12.
    A. Taghian, J. Ramsay, J. Allalunis-Turner, et al., Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme. Int., J. Radiat. Oncol. Biol. Phys. 25: 243–249, 1993.CrossRefGoogle Scholar
  13. 13.
    R. Rampling, G. Cruickshank, A. Lewis, et al., Direct measurement of p02 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys, 29: 427–431, 1994.PubMedCrossRefGoogle Scholar
  14. 14.
    A.J. van der Kogel, Radiation injury in the central nervous system. in Radiation Injury to the Nervous System, New York, Raven Press, 1991. pp 43–50.Google Scholar
  15. 15.
    P.R. Gavin, S.L. Kraft, C.E. DeHaan et al., Large animal normal tissue tolerance with boron neutron capture, Int. J. Radiat. Oncol. Biol. Phys. 28: 1099–1106, 1994.PubMedCrossRefGoogle Scholar
  16. 16.
    N. Gupta, R.A. Gahbauer, T.E. Blue, et al., Dose prescription in boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 28: 1157–1166, 1994.PubMedCrossRefGoogle Scholar
  17. 17.
    D.W. Nigg., Methods for radiation dose distribution analysis and treatment planning in boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 28: 1121–1134, 1994.Google Scholar
  18. 18.
    R.K. Jain, Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81: 570–576, 1989.PubMedCrossRefGoogle Scholar
  19. 19.
    N.H. Greig, Drug delivery to the brain by blood–brain barrier circumvention and drug modification in Implications of the Blood-Brain Barrier and Its Manipulation. Vol. I. ed. E.A. Neuwelt. Plenum Press, 1989, pp 311–367.CrossRefGoogle Scholar
  20. 20.
    M. Liebert, R.L. Walsh, G. Lawless et al., Direct stereotactic intracerebral injection of monoclonal antibodies and their fragments: a potential approach to brain tumor immunotherapy, Amer. J. of Physiologic Imaging 5: 55–59, 1990.Google Scholar
  21. 21.
    P. Riva, A. Arista, C. Sturiale et al., Treatment of intracranial htiman glioblastoma by direct intritumoral administration of 1311-labelled anti-tenascin monoclonal antibody BC-2, Int J. Cancer 51, 7–13, 1992PubMedCrossRefGoogle Scholar
  22. 22.
    T. Hoshino, D. Ahn, M.D. Prados, et al., Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling. Int J. Cancer. 53: 550–555, 1993.PubMedCrossRefGoogle Scholar
  23. 23.
    G.G. Steel, The heyday of cell population kinetics: Insights from the 1960s and 1970s. Seminars in Radiation Oncology. 3: 78–83, 1993.PubMedCrossRefGoogle Scholar
  24. 24.
    J.G. Tjuvajev, H.A. Macapinac, F. Daghighian, et al., Imaging of brain tumor proliferative activity with iodine- 131 -iododeoxyuridine. J Nucl. Med. 35: 1407–1417, 1994.PubMedGoogle Scholar
  25. 25.
    P. McKeever, D. Robertson, P. Shakui, Patterns of antigenic expression of human glioma cells, CRC Crit Rev in Neuorbiol. 6: 119–147, 1990.Google Scholar
  26. 26.
    R.F. Barth, A.H. Soloway, F. Alam et al., Neutron capture using boronated polyclonal and monoclonal antibodies. Proc First Intl Symposium on Neutron Capture Therapy Brookhaven National Laboratory Report BNL 51730: 365–375, 1984.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Rolf F. Barth
    • 1
  1. 1.Department of PathologyThe Ohio State UniversityColumbusUSA

Personalised recommendations